DR. KEVIN SUE WEIBEL D.O. NPI 1104864016

NPI Details

DR. Kevin Sue Weibel, D.O. is a hematology and oncology internal medicine in Tulsa, OK with 40 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Kevin Sue Weibel, D.O. NPI is 1104864016. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: OKLAHOMA STATE UNIVERSITY COLLEGE OF OSTEOPATHIC MEDICINE
Graduation Year:1985

The provider's business location address is:

12697 E 51ST ST
TULSA, OK
ZIP 74146-236
Phone: (918) 505-3200
Fax: (918) 505-3253

The NPI 1104864016 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, docetaxel, 1 mg (HCPCS:J9171)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg (HCPCS:Q5116)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, granisetron, extended-release, 0.1 mg (HCPCS:J1627)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Magnesium level (HCPCS:83735)
• Phosphate level (HCPCS:84100)
• Uric acid level, blood (HCPCS:84550)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml (HCPCS:A9579)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Ct scan of chest with contrast (HCPCS:71260)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Unclassified drugs (HCPCS:J3490)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Blood creatinine level (HCPCS:82565)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Red blood cell sedimentation rate, to detect inflammation, automated (HCPCS:85652)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Manual urinalysis test with examination using microscope, automated (HCPCS:81001)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Red blood count, automated test (HCPCS:85045)
• Mri scan of brain before and after contrast (HCPCS:70553)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Automated urinalysis test (HCPCS:81003)
• Ct scan of soft tissue of neck with contrast (HCPCS:70491)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries (HCPCS:A9561)
• Nuclear medicine study whole body with ct scan (HCPCS:78816)
• X-ray of chest, 2 views (HCPCS:71046)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0221)
• Nuclear medicine study of bone and/or joint whole body (HCPCS:78306)
• Nuclear medicine study of heart pumping function by labeling red blood cells with measurement of internal blood volume ejected with every beat over multiple cycles (HCPCS:78472)
• Declotting of central venous tube (HCPCS:36593)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Technetium tc-99m labeled red blood cells, diagnostic, per study dose, up to 30 millicuries (HCPCS:A9560)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Mri scan of abdomen before and after contrast (HCPCS:74183)
• Stool analysis for blood, by fecal hemoglobin determination by immunoassay (HCPCS:82274)

The enumeration date for this NPI number is 6/3/2006 and was last updated on 5/8/2014.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: